LIXTNasdaq

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Healthcare·Oncology·Phase 1·Boca Raton, FL, United States
Oncology

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT): 2 pipeline candidates. Updated within the last hour.

6.1/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health9.7

D/E 0.21 · 0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for LIXTE BIOTECHNOLOGY HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$113.2M

Cash

—

Quarterly Burn

$1.8M

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
lb-100Phase 1
lb-200Preclinical

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

13

Total value held

$2.3M

HolderSharesValue
scotia capital inc.283,162$869K
vanguard capital management llc98,958$304K
renaissance technologies llc93,000$286K
federation des caisses desjardins du quebec64,487$198K
geode capital management, llc58,852$181K
citadel advisors llc56,557$174K
vanguard fiduciary trust co35,034$108K
xtx topco ltd23,446$72K
state street corp17,396$53K
atlas legacy advisors, llc13,771$42K

Showing top 10 of 13 institutional holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Geordan G. Pursglove

Frequently asked questions

How many drug candidates are in LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s pipeline?

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s lead drug candidate?

LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s most advanced tracked candidate is lb-100 (Phase 1) for Advanced Soft Tissue Sarcoma.

What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s market capitalization?

LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s market capitalization is approximately $113.2M.

Who is the CEO of LIXTE BIOTECHNOLOGY HOLDINGS, INC.?

Mr. Geordan G. Pursglove is the chief executive officer of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).

Get the full picture on LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar